Merck may have solved the hidden problem behind the oral PCSK9 race
Oral PCSK9 drugs need more than strong LDL data. Merck’s enlicitide paper tests whether peptide manufacturing can scale.
Can Merck’s enlicitide decanoate become the oral PCSK9 breakthrough cholesterol care has been waiting for?
Merck’s enlicitide decanoate beat oral rivals in Phase 3. Read what this could change for cholesterol care, PCSK9 adoption, and market strategy.